{"nctId":"NCT01719003","briefTitle":"Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes","startDateStruct":{"date":"2012-10"},"conditions":["Diabetes Mellitus, Type 2","Hyperglycemia"],"count":1413,"armGroups":[{"label":"Empagliflozin low dose qd","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin low dose qd"]},{"label":"Empagliflozin high dose qd","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin high dose qd"]},{"label":"OL empa high dose + met 1000 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin 1000 mg bid","Drug: Empagliflozin high dose bid"]},{"label":"Empagliflozin low dose + met 500 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin 500 mg bid","Drug: Empagliflozin low dose bid"]},{"label":"Empagliflozin low dose + met 1000 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin low dose bid","Drug: Metformin 1000 mg bid"]},{"label":"Empagliflozin high dose + met 500 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin 500 mg bid","Drug: Empagliflozin high dose bid"]},{"label":"Empagliflozin high dose + met 1000mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin 1000 mg bid","Drug: Empagliflozin high dose bid"]},{"label":"Metformin 500 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin 500 mg bid"]},{"label":"Metformin 1000 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin 1000 mg bid"]}],"interventions":[{"name":"Metformin 500 mg bid","otherNames":[]},{"name":"Metformin 1000 mg bid","otherNames":[]},{"name":"Empagliflozin low dose qd","otherNames":[]},{"name":"Empagliflozin high dose qd","otherNames":[]},{"name":"Empagliflozin low dose bid","otherNames":[]},{"name":"Metformin 500 mg bid","otherNames":[]},{"name":"Empagliflozin high dose bid","otherNames":[]},{"name":"Empagliflozin low dose bid","otherNames":[]},{"name":"Metformin 1000 mg bid","otherNames":[]},{"name":"Metformin 500 mg bid","otherNames":[]},{"name":"Metformin 1000 mg bid","otherNames":[]},{"name":"Empagliflozin high dose bid","otherNames":[]},{"name":"Metformin 1000 mg bid","otherNames":[]},{"name":"Empagliflozin high dose bid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of type 2 diabetes mellitus prior to informed consent\n2. Male and female patients on diet and exercise regimen who are drug-naive, defined as absence of any oral antidiabetic therapy for 12 weeks prior to randomization\n3. HbA1c \\>=7.5% and \\<= 12% (\\>=58.5 mmol/mol and \\<=107.7 mmol/mol)\n4. Body Mass Index (BMI) \\<= 45 kg/m2 at screening\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycemia with a glucose level \\>240 mg/dl (\\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second laboratory measurement (not on the same day)\n2. Any antidiabetic drug within 12 weeks prior to randomization\n3. Impaired renal function, defined as estimated creatinine clearance rate (eCCr) \\<60 ml/min (Cockcroft-Gault formula) as determined during screening and/or run-in period\n4. Contraindications to metformin according to the local label","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24","description":"Change from baseline in HbA1c (%) after 24 weeks of treatment. \"Baseline\" refers to the last observation before the start of any randomised trial treatment medication. Means presented are the adjusted means","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"0.08"},{"groupId":"OG001","value":"-1.93","spread":"0.08"},{"groupId":"OG002","value":"-2.07","spread":"0.08"},{"groupId":"OG003","value":"-1.98","spread":"0.08"},{"groupId":"OG004","value":"-1.36","spread":"0.08"},{"groupId":"OG005","value":"-1.35","spread":"0.08"},{"groupId":"OG006","value":"-1.75","spread":"0.09"},{"groupId":"OG007","value":"-1.18","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"FPG (Fasting Plasma Glucose) Change From Baseline at Week 24","description":"Change from baseline in FPG (mg/dL) after 24 weeks of treatment. \"Baseline\" refers to the last observation before the start of any randomised trial treatment medication. Means presented are the adjusted means.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.0","spread":"2.4"},{"groupId":"OG001","value":"-44.0","spread":"2.4"},{"groupId":"OG002","value":"-47.8","spread":"2.4"},{"groupId":"OG003","value":"-45.5","spread":"2.4"},{"groupId":"OG004","value":"-28.0","spread":"2.5"},{"groupId":"OG005","value":"-32.9","spread":"2.4"},{"groupId":"OG006","value":"-32.1","spread":"2.4"},{"groupId":"OG007","value":"-17.2","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Body Weight Change From Baseline at Week 24","description":"Change from baseline in body weight (kg) after 24 weeks of treatment. \"Baseline\" refers to the last observation before the start of any randomised trial treatment. medication. Means presented are the adjusted means.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.78","spread":"0.29"},{"groupId":"OG001","value":"-3.04","spread":"0.30"},{"groupId":"OG002","value":"-3.48","spread":"0.30"},{"groupId":"OG003","value":"-2.77","spread":"0.30"},{"groupId":"OG004","value":"-2.38","spread":"0.30"},{"groupId":"OG005","value":"-2.39","spread":"0.29"},{"groupId":"OG006","value":"-1.27","spread":"0.30"},{"groupId":"OG007","value":"-0.52","spread":"0.30"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":170},"commonTop":["Urinary tract infection","Dyslipidaemia","Diarrhoea","Upper respiratory tract infection","Dizziness"]}}}